Stem Cell SARS-CoV-2 Vaccine Antigen Presentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current SARS-COV-2 vaccine research primarily focuses on traditional inactivated or attenuated vaccines, nucleic acid vaccines, and viral vector vaccines, which may require repeated immunizations, cause discomfort, and have limitations such as short immunization periods and potential immune resistance issues, with no cell delivery platform-based vaccines reported.

Innovation Solution

Development of a cell-mediated SARS-COV-2 vaccine using stem cells to present and secrete essential viral proteins, inducing immune memory and broad-spectrum antibody production, thereby overcoming traditional vaccine limitations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If traditional inactivated or attenuated vaccines are used, then vaccine production is straightforward, but multiple immunization injections are required and the immunization period is short

Engineering Contradiction:

Improvevaccine production easeVSAvoidimmunization period

Core Design Contradiction:

Ease of manufactureVSDuration of action of moving object

Solution Approach 1:

The patent uses stem cells as an intermediary carrier to deliver viral proteins into the body. These stem cells act as a mediator between the vaccine antigens and the immune system, enabling long-term antigen presentation and sustained immune activation without requiring multiple injections

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The stem cells are pre-modified ex vivo to express viral proteins before administration. This preliminary preparation allows the cells to immediately begin antigen presentation upon injection, establishing long-term immune memory in a single dose without needing subsequent boosters

Inventive Principle:

Principle #10Preliminary action

2Reliability

If viral vector vaccines are used, then immune response can be stimulated, but immune resistance may develop limiting vaccine effectiveness

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidimmune resistance development

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent replaces viral vectors with stem cells as the delivery intermediary. Stem cells naturally express viral proteins without triggering pre-existing immunity against delivery vectors, thereby avoiding immune resistance while maintaining effective antigen presentation and immune response stimulation

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

Instead of using viral vectors to deliver genetic instructions, the patent directly copies the viral protein expression function into stem cells through genetic modification. This creates a non-viral system that replicates the antigen-presenting function without the immunogenicity problems of viral delivery systems

Inventive Principle:

Principle #26Copying

3Reliability

If traditional vaccines are used, then immunization can be achieved, but repeated injections cause discomfort and require multiple visits

Engineering Contradiction:

Improveimmunization effectivenessVSAvoidimmunization convenience

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The stem cells are pre-engineered ex vivo to contain and express multiple viral antigens simultaneously. This preliminary preparation consolidates what would traditionally require multiple separate injections into a single cell-based vaccine administration, improving convenience while maintaining immunization effectiveness

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent merges multiple antigen delivery functions into a single stem cell platform. By engineering stem cells to express multiple viral proteins simultaneously, it combines what would traditionally require multiple injection sessions into one administration, reducing patient burden while achieving comprehensive immune coverage

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The stem cell-based vaccine accelerates antibody production, avoids adverse immune responses, and achieves high success rates with a single immunization, providing long-term immune memory and timeliness in antibody detection, outperforming traditional vaccines in safety and efficacy.

Implementation Method 1

stem cells to present and secrete essential viral proteins

Methodology Applied

Scientific EffectProtein secretion:

Implementation Method 2

inducing immune memory and broad-spectrum antibody production

Methodology Applied

Scientific EffectImmune response induction:

Data Source

PatentUS20230227844A1Cell-mediated SARS-COV-2 vaccines, and preparation and use thereof

Publication Date: 2023.07.20 YIN XIUSHAN

AI summary

Provided are a cell-mediated SARS-COV-2 vaccine and a preparation method therefor, the steps therefor including: the construction of a SARS-COV-2 specific antigen vector presented by stem cells, and the modification and assembly with the stem cells. Two weeks after mouse immunization, approximately 50% of the mice have in vivo antibodies that show a strong positive expression, and the most significant of which being an N-gene modified stem cell vaccine.